Clinical Trials Directory

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer's disease.

Stanford is now accepting new patients for this trial. Please contact Christina Wyss-Coray at 650-721-2409 for more information.


  • drug : MABT5102A
  • drug : placebo
  • drug : placebo

Phase: Phase 2


Ages Eligible For Study:

50 Years - 80 Years

Inclusion Criteria

- Diagnosis of probable AD according to the NINCDS-ADRDA criteria - MMSE score of 18-26 points at screening - GDS-15 score of < 6 - Completion of 6 years of education (or good work history consistent with exclusion of mental retardation or other pervasive developmental disorders) - For patients currently receiving treatment with approved AD treatments (AChE inhibitors or memantine): Treatment initiated and continued for at least the last 3 months prior to randomization, at a stable dose for at least the last 2 months prior to randomization

External Links

Explore related trials

Contact information

Primary Contact:

Christina Wyss-Coray 650-721-2409

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: